Bioactive Secondary Metabolites from Marine Microbes for Drug Discovery

Advances in Food and Nutrition Research

Volumn 65, Issue , 2012, Pages 363-387

  Nikapitiya, Chamilani ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Actinomycetes; Anti HIV; Anticancer; Cyanobacteria; Fungi; Marine bacteria; Marine microbes; Marine secondary metabolites; Multidrug resistant

Indexed keywords

EID: 84857203604     PISSN: 10434526     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416003-3.00024-X     Document Type: Chapter

References (158)

1. Abadi G., Palen W., Geddings J., Irwin T., Kasali N., Colyer J., Goodsen F., Smith J., Jones K., Loftis R., Hester J., Noble L., et al. A history of bryostatins: A prominent marine natural product, recent progress in medicinal plants. Recent. Prog. Med. Plants 2006, 15:370-411.
2. Ahn K.S., Sethi G., Chao T.H., Neuteboom S.T., Chaturvedi M.M., Palladino M.A., Younes A., Aggarwal B.B. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis and inhibits invasion through down-modulation of NF-kB-regulated gene products. Blood 2007, 10:2286-2295.
3. Anson B.D., Ma J., He J.Q. Identifying cardiotoxic compounds. Genet. Eng. Biotechnol. News 2009, 29(9):1-2.
4. Arena A., Gugliandolo C., Stassi G., Pavone B., Iannello D., Bisignano G., Maugeri T.L. An exopolysaccharide produced by Geobacillus thermodenitrificans strain B3-72: Antiviral activity on immunocompetent cells. Immunol. Lett. 2009, 123(2):132-137.
5. Barrios-Llerena M.E., Burja A.M., Wright P.C. Genetic analysis of polyketide synthase and peptide synthetase genes in cyanobacteria as a mining tool for secondary metabolites. J. Ind. Microbiol. Biotechnol. 2007, 34(6):443-456.
6. Bhadury P., Mohammad B.T., Wright P.C. The current status of natural products from marine fungi and their potential as anti-infective agents. J. Ind. Microbiol. Biotechnol. 2006, 33:325-337.
7. Bhatnagar I., Kim S.K. Immense essence of excellence: Marine microbial bioactive compounds. Mar. Drugs 2010, 8:2673-2701.
8. Blunt J.W., Copp B.R., Munro M.H.G., Northcote P.T., Prinsep M.R. Marine natural products. Nat. Prod. Rep. 2004, 21(1):1-49.
9. Blunt J.W., Copp B.R., Munro M.H.G., Northcote P.T., Prinsep M.R. Marine natural products. Nat. Prod. Rep. 2005, 22(1):15-61.
10. Blunt J.W., Copp B.R., Munro M.H.G., Northcote P.T., Prinsep M.R. Marine natural products. Nat. Prod. Rep. 2006, 23(1):26-78.
11. Blunt J.W., Copp B.R., Hu W.P., Munro M.H., Northcote P.T., Prinsep M.R. Marine natural products. Nat. Prod. Rep. 2007, 24(1):31-86.
12. Boonlarppradab C., Kauffman C.A., Jensen P.R., Fenical W. Marineosins A and B, cytotoxic spiroaminals from a marine-derived actinomycete. Org. Lett. 2008, 10(24):5505-5508.
13. Bowers A., West N., Taunton J., Schreiber S.L., Bradner J.E., Williams R.M. Total synthesis and biological mode of action of largazole: A potent class I histone deacetylase inhibitor. J. Am. Chem. Soc. 2008, 130(33):11219-11222.
14. Bull A.T., Stach J.E.M. Marine actinobacteria: New opportunities for natural product search and discovery. Trends Microbiol. 2007, 15(11):491-499.
15. Burkholder P., Pfister R., Leitz F. Production of a pyrrole antibiotic by a marine bacterium. Appl. Microbiol. 1966, 14(4):649-653.
16. Butler M.S. Natural products to drugs: Natural product-derived compounds in clinical trials. Nat. Prod. Rep. 2008, 25:475-516.
17. Canedo L.M., Fernández-Puentes J.L., Baz J.P. IB-96212, a novel cytotoxic macrolide produced by a marine Micromonospora. II. Physico-chemical properties and structure determination. J. Antibiot. (Tokyo) 2000, 53(5):479-483.
18. Carte B.K. Biomedical potential of marine natural products. Bioscience 1996, 46:271-286.
19. Chang M.C.Y., Keasling J.D. Production of isoprenoid pharmaceuticals by engineered microbes. Nat. Chem. Biol. 2006, 2:674-681.
20. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., Ovaa H., Berkers C., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8(5):407-419.
21. Clamp A.I., Jayson G.C.I. The clinical development of the bryostatins. Anti-Cancer Drugs 2002, 13(7):673-683.
22. Clark B.R., Engene N., Teasdale M.E., Rowley D.C., Matainaho T., Valeriote F.A., Gerwick W.H. Natural products chemistry and taxonomy of the marine cyanobacterium Blennothrix cantharidosmum. J. Nat. Prod. 2008, 71(9):1530-1537.
23. Cox R.J. Polyketides, proteins and genes in fungi: Programmed nano-machines begin to reveal their secrets. Org. Biomol. Chem. 2007, 5:2010-2026.
24. Cragg G.M., Newman D.J. Medicinals for the millennia: The historical record. Ann. NY Acad. Sci. 2001, 953:3-25.
25. Davidson B.S. New dimensions in natural products research: Cultured marine microorganisms. Curr. Opin. Biotechnol. 1995, 6(3):284-291.
26. Davidson S.K., Allen S.W., Lim G.E., Anderson C.M., Haygood M.G. Evidence for the biosynthesis of bryostatins by the bacterial symbiont "Candidatus Endobugula sertula" of the bryozoan Bugula neritina. Appl. Environ. Microbiol. 2001, 67(10):4531-4537.
27. Ducklow H. Bacterial production and biomass in the oceans. Microbial Ecology of the Oceans 2000, 85-120. Wiley, New York, NY. D.L. Kirchman (Ed.).
28. Egan S., James S., Holmström C., Kjelleberg S. Correlation between pigmentation and antifouling compounds produced by Pseudoalteromonas tunicata. Environ. Microbiol. 2002, 4(8):433-442.
29. El-Gendy M.M.A., Shaaban M., Shaaban K.A., El-Bondkly A.M., Laatsch H. Essramycin: A first triazolopyrimidine antibiotic isolated from nature. J. Antibiot (Tokyo) 2008, 61:149-157.
30. El-Gendy M.M., Hawas U.W., Jaspars M. Novel bioactive metabolites from a marine derived bacterium Nocardia sp. ALAA 2000. J. Antibiot. (Tokyo) 2008, 61(6):379-386.
31. Faulkner D. Biomedical uses for natural marine chemicals. J. Oceanus 1992, 35:29-35.
32. Faulkner D.J. Marine natural products. Nat. Prod. Rep. 1997, 14(3):259-302.
33. Faulkner D.J. Marine natural products. Nat. Prod. Rep. 2000, 17(1):7-55.
34. Faulkner D.J. Marine natural products. Nat. Prod. Rep. 2001, 18(1):1-49.
35. Feher M., Schmidt J.M. Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 2003, 43(1):218-227.
36. Feher D., Barlow R., McAtee J., Hemscheidt T.K. Highly brominated antimicrobial metabolites from a marine Pseudoalteromonas sp. J. Nat. Prod. 2010, 73(11):1963-1966.
37. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., Fenical W. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed Engl. 2003, 42(3):355-357.
38. Fenical W. Chemical studies of marine bacteria: Developing a new resource. Chem. Rev. 1993, 93(5):1673-1683.
39. Fenical W. Marine bacteria: Developing a new chemical resource. Chem. Rev. 1993, 93:1673-1683.
40. Fenical W., Jensen P.R. Developing a new resource for drug discovery: Marine actinomycete bacteria. Nat. Chem. Biol. 2006, 2:666-673.
41. Franks A., Haywood P., Holmström C., Egan S., Kjelleberg S., Kumar N. Isolation and structure elucidation of a novel yellow pigment from the marine bacterium Pseudoalteromonas tunicata. Molecules 2005, 10(10):1286-1291.
42. Galm U., Shen B. Natural product drug discovery: The times have never been better. Chem. Biol. 2007, 14:1098-1104.
43. Gil-Turnes M.S., Hay M.E., Fenical W. Symbiotic marine bacteria chemically defend crustacean embryos from a pathogenic fungus. Science 1989, 246(4926):116-118.
44. Grabowski K., Schneider G. Properties and architecture of drugs and natural products revisited. Curr. Chem. Biol. 2007, 1:115-127.
45. Groll M., Huber R., Potts B.C. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 2006, 128:5136-5141.
46. Gulder A.M.G., Moore B.S. Chasing the treasures of the sea-bacterial marine natural products. Curr. Opin. Microb. 2009, 12:252-260.
47. Gustafson K., Roman M., Fenical W. The macrolactins, a novel class of antiviral and cytotoxic macrolides from a deep-sea marine bacterium. J. Am. Chem. Soc. 1989, 111(19):7519-7524.
48. Hale K.J., Hummersone M.G., Manaviazar S., Frigerio M. The chemistry and biology of the bryostatin antitumour macrolides. Nat. Prod. Rep. 2002, 19:413-453.
49. Harvey A. Strategies for discovering drugs from previously unexplored natural products. Drug Discov. Today 2000, 5(7):294-300.
50. Harvey A.L. Natural products as a screening resource. Curr. Opin. Chem. Biol. 2007, 11(5):480-484.
51. Harvey A.L. Natural products in drug discovery. Drug Discov. Today 2008, 13(19/20):894-901.
52. Hehemann J.H., Correc G., Barbeyron T., Helbert W., Czjzek M., Michel G. Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota. Nature 2010, 464:908-912.
53. Hill R.A. Marine natural products. Annu. Rep. Prog. Chem. Sect. B. 2003, 99:183-207.
54. Hughes C.C., Prieto-Davo A., Jensen P.R., Fenical W. The marinopyrroles, antibiotics of an unprecedented structure class from marine Streptomyces sp. Org. Lett. 2008, 10:629-631.
55. Hughes C.C., MacMillan J.B., Gaudêncio S.P., Jensen P.R., Fenical W. The ammosamides: Structures of cell cycle modulators from a marine-derived Streptomyces species. Angew. Chem. Int. Ed. 2009, 48(4):725-727.
56. Isnansetyo A., Kamei Y. MC21-A, a bacterial antibiotic produced by a new marine bacterium, Pseudoalteromonas phenolica sp. nov. O-BC30T against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2003, 47:480-488.
57. Isnansetyo A., Kamei Y. Bioactive substances produced by marine isolates of Pseudomonas. J. Ind. Microbiol. Biotechnol. 2009, 36:1239-1248.
58. Iwata F., Sato S., Mukai T., Yamada S., Takeo J., Abe A., Okita T., Kawahara H. Lorneic acids, trialkyl-substituted aromatic acids from a marine-derived actinomycete. J. Nat. Prod. 2009, 72(11):2046-2048.
59. Jain R., Tiwari A. Sponges: An invertebrate of bioactive potential. Curr. Sci. 2007, 93:444-445.
60. Jaiswal P., Singh P.K., Prasanna R. Cyanobacterial bioactive molecules-An overview of their toxic properties. Can. J. Microbiol. 2008, 54(9):701-717.
61. Jensen P.R., Dwight R., Fenical W. Distribution of actinomycetes in near-shore tropical marine sediments. Appl. Environ. Microbiol. 1991, 57(4):1102-1108.
62. Jensen P.R., Mincer T.J., Williams P.G., Fenical W. Marine actinomycete diversity and natural product discovery. Antonie Van Leeuwenhoek 2005, 87:43-48.
63. Jha R.K., Zi-rong X. Biomedical compounds from marine organisms. Mar. Drugs 2004, 2:123-146.
64. Kamei Y., McCarthy S.A., Kakimoto D., Johnson R. Inhibition of Paramecium caudatum by an Alteromonas luteoviolacea antibiotic. Antimicrob. Agents Chemother. 1986, 30:301-303.
65. Kanoh K., Yoshihide M., Kyoko A., Hiroshi I., Mugio N., Yoshikazu S. Mechercharmycins A and B, cytotoxic substances from marine-derived Thermoactinomyces sp. YM3-251. J. Antibiot. 2005, 58(4):289-292.
66. Kanoh K., Okada A., Adachi K., Imagawa H., Nishizawa M., Matsuda S., Shizuri Y., Utsumi R. Ascochytatin, a novel bioactive spirodioxynaphthalene metabolite produced by the marine-derived fungus, Ascochyta sp. NGB4. J. Antibiot. (Tokyo) 2008, 61:142-148.
67. Kanoh K., Adachi K., Matsuda S., Shizuri Y., Yasumoto K., Kusumi T., Okumura K., Kirikae T. New sulfoalkylresorcinol from marine-derived fungus, Zygosporium sp. KNC52. J. Antibiot. (Tokyo) 2008, 61(3):192-194.
68. Kasettrathat C., Ngamrojanavanich N., Wiyakrutta S., Mahidol C., Ruchirawat S., Kittakoop P. Cytotoxic and antiplasmodial substances from marine-derived fungi, Nodulisporium sp. and CRI247-01. Phytochemistry 2008, 69(14):2621-2626.
69. Kennedy J. Mutasynthesis, chemobiosynthesis, and back to semi-synthesis: Combining synthetic chemistry and biosynthetic engineering for diversifying natural products. Nat. Prod. Rep. 2008, 25:25-34.
70. Kennedy J., Marchesi J.R., Dobson A.D.W. Metagenomic approaches to exploit the biotechnological potential of the microbial consortia of marine sponges. Appl. Microb. Biotechnol. 2007, 75(1):11-20.
71. Kijjoa A., Sawangwong P. Drugs and cosmetics from the sea. Mar. Drugs 2004, 2004:73-82.
72. Kingston D.G.I. Modern natural products drug discovery and its relevance to biodiversity conservation. J. Nat. Prod. 2011, 74(3):496-511.
73. Kjer J., Debbab A., Aly A.H., Proksch P. Methods for isolation of marine-derived endophytic fungi and their bioactive secondary products. Nature Protoc. 2010, 5:479-490.
74. Kobayashi J., Ishibashi M. Bioactive metabolites of symbiotic marine microorganisms. Chem. Rev. 1993, 93(5):1753-1769.
75. Konig G.M., Wright A.D. Trends in marine biotechnology. Drugs Discovery from Nature 1999, 180-187. Springer-Verlag, Berlin, Heidelberg. S. Grabley, R. Thiericke (Eds.).
76. Kopp F., Marahiel M.A. Where chemistry meets biology: The chemoenzymatic synthesis of nonribosomal peptides and polyketides. Curr. Opin. Biotechnol. 2007, 18(6):513-520.
77. Kwon H.C., Espindola A.P.D.M., Park J.S., Prieto-Dav A., Rose M., Jensen P.R., Fenical W. Nitropyrrolins A-E, cytotoxic farnesyl-α-nitropyrroles from a marine-derived bacterium within the actinomycete family Streptomycetaceae. J. Nat. Prod. 2010, 73(12):2047-2052.
78. Laatsch H., Rennerberg B., Hanefeld U., Kellner M., Pudleine H., Hamprecht G., Kraemer H., Anke H. Structure-activity relationship of phenyl- and benzoylpyrroles. Chem. Pharm. Bull. 1995, 43(4):537-546.
79. Lee S.U., Asami Y., Lee D., Jang J.H., Ahn J.S., Oh H. Protuboxepins A and B and Protubonines A and B from the marine-derived fungus Aspergillus sp. SF-5044. J. Nat. Prod. 2011, 74(5):1284-1287.
80. Lefevre F., Robe P., Jarrin C., Ginolhac A., Zago C., Auriol D., Vogel T.M., Simonet P., Nalin R. Drugs from hidden bugs: Their discovery via untapped resources. Res. Microbiol. 2008, 159(3):153-161.
81. Li X., Qin L. Metagenomics-based drug discovery and microbial diversity. Trends Biotechnol. 2005, 23(11):539-543.
82. Li L., Deng W., Song J., Ding W., Zhao Q.F., Peng C., Song W.W., Tang G.L., Liu W. Characterization of the saframycin A gene cluster from Streptomyces lavendulae NRRL 11002 revealing a nonribosomal peptide synthetase system for assembling the unusual tetrapeptidyl skeleton in an iterative manner. J. Bacteriol. 2008, 190(1):1251-1263.
83. Li C.S., An C.Y., Li X.M., Gao S.S., Cui C.M., Sun H.F., Wang B.G. Triazole and dihydroimidazole alkaloids from the marine sediment-derived fungus Penicillium paneum SD-44. J. Nat. Prod. 2011, 74(5):1331-1334.
84. Li D., Carr G., Zhang Y., Williams D.E., Amlani A., Bottriell H., Mui A.L.F., Andersen R.J. Turnagainolides A and B, cyclic depsipeptides produced in culture by a Bacillus sp.: Isolation, structure elucidation, and synthesis. J. Nat. Prod. 2011, 74(5):1093-1099.
85. Liang T. Investigation of secondary metabolites of North Sea bacteria: Fermentation, isolation, structure elucidation and bioactivity 2003, PhD thesis. University of Gottingen.
86. Lindquist N., Fenical W. New tambjamine class alkaloids from the marine ascidian Atapozoa sp. and its nudibranch predators-Origins of the tambjamines in atapozoa. Experientia 1991, 47:504-508.
87. Linington R.G., Clark B.R., Trimble E.E., Almanza A., Urena L.D., Kyle D.E., Gerwick W.H. Antimalarial peptides from marine cyanobacteria: Isolation and structural elucidation of gallinamide A. J. Nat. Prod. 2009, 72(1):14-17.
88. Long P.F., Dunlap W.C., Battershill C.N., Jaspars M. Shotgun cloning and heterologous expression of the patellamide gene cluster as a strategy to achieving sustained metabolite production. Chem. Bio. Chem. 2005, 6:1760-1765.
89. Lopes V.R., Fernández N., Martins R.F., Vasconcelos V. Primary screening of the bioactivity of Brackishwater cyanobacteria: Toxicity of crude extracts to Artemia salina larvae and Paracentrotus lividus embryos. Mar. Drugs 2010, 8(3):471-482.
90. Lu Z., Wang Y., Miao C., Liu P., Hong K., Zhu W. Sesquiterpenoids and benzofuranoids from the marine-derived fungus Aspergillus ustus 094102. J. Nat. Prod. 2009, 72(10):1761-1767.
91. Lu Z., Zhu H., Fu P., Wang Y., Zhang Z., Lin H., Liu P., Zhuang Y., Hong K., Zhu W. Cytotoxic polyphenols from the marine-derived fungus Penicillium expansum. J. Nat. Prod. 2010, 73(5):911-914.
92. Luesch H., Moore R.E., Paul V.J., Mooberry S.L., Corbett T.H. Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J. Nat. Prod. 2001, 64(7):907-910.
93. MacMillan J.B., Molinski T.F. Caylobolide A, a unique 36-membered macrolactone from a Bahamian Lyngbya majuscule. Org. Lett. 2002, 4(9):1535-1538.
94. Maloney K.N., MacMillan J.B., Kauffman C.A., Jensen P.R., DiPasquale A.G., Rheingold A.L., Fenical W. Lodopyridone, a structurally unprecedented alkaloid from a marine actinomycete. Org. Lett. 2009, 11(23):5422-5424.
95. Mann J. Natural products in cancer: Chemotherapy: Past, present and future. Nat. Rev. Cancer 2002, 2:143-148.
96. Maskey R.P., Li F.C., Qin S., Fiebig H.H., Laatsch H. Chandrananimycins A-C: Production of novel anticancer antibiotics from a marine Actinomadura sp. isolate M048 by variation of marine composition and growth conditions. J. Antibiot. 2003, 56(7):622-629.
97. Maskey R.P., Helmke E., Kayser O., Fiebig H.H., Maier A., Busche A., Laatsch H. Anti-cancer and antibacterial trioxacarcins with high anti-malaria activity from a marine Streptomycete and their absolute stereochemistry. J. Antibiot. (Tokyo) 2004, 57(12):771-779.
98. Mayer A.M.S., Lehmann V.K.B. Marine pharmacology in 1998: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, anthelminitic, antiplatelet, antiprotozoal, and antiviral activities with actions on the cardiovascular, endocrine, immune, and nervous systems, and other miscellaneous mechanisms of action. Pharmacologist 2000, 42:62-69.
99. Mayer A.M., Glaser K.B., Cuevas C., Jacobs R.S., Kem W., Little R.D., McIntosh J.M., Newman D.J., Potts B.C., Shuster D.E. The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends Pharmacol. Sci. 2010, 31(6):255-265.
100. McArthur K.A., Mitchell S.S., Tsueng G., Rheingold A., White D.J., Grodberg J., Lam K.S., Potts B.C. Lynamicins A-E, chlorinated bisindole pyrrole antibiotics from a novel marine actinomycete. J. Nat. Prod. 2008, 71(10):1732-1737.
101. Medina R.A., Goeger D.E., Hills P., Mooberry S.L., Huang N., Romero L.I., Ortega-Barra E., Gerwick W.H., McPhail K.L. Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium Leptolyngbya sp. J. Am. Chem. Soc. 2008, 130(20):6324-6325.
102. Mendola D. Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: Process developments and economics. Biomol. Eng. 2003, 20:441-458.
103. Mevers E., Liu W.T., Engene N., Mohimanis H., Byrum T., Pevzner P.A., Dorrestein P.C., Spadafora C., Gerwick W.H. Cytotoxic veraguamides, alkynyl bromide-containing cyclic depsipeptides from the marine cyanobacterium cf. Oscillatoria margaritifera. J. Nat. Prod. 2011, 74(5):928-936.
104. Mincer T.J., Jensen P.R., Kauffman C.A., Fenical W. Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments. Appl. Environ. Microbiol. 2002, 68(10):5005-5011.
105. Moore B.S., Seng D. Biosynthesis of the bicyclic depsipeptide salinamide A in Streptomyces sp. CNB-091: Origin of the carbons. Tetrahedron Lett. 1998, 39(23):3915-3918.
106. Moore B.S., Trischman J.A., Seng D., Kho K., Jensen D.P.R., Fenical W. Salinamides, antiinflammatory depsipeptides from a marine Streptomycete. J. Org. Chem. 1999, 64(4):1145-1150.
107. Sc )-induced toxicity in rat cortical cell culture. Eur. J. Pharmacol. 1993, 246:261-267.
108. Muller W.E.G., Romero F.J., Perovic S., Pergande G., Pialoglou P. Protection of flupirtine on β-amyloid-induced apoptosis in neuronal cells in vitro. Prevention of amyloid-induced glutathione depletion. J. Neurochem. 1997, 68:2371-2377.
109. Murakami R., Shinozaki J., Kajiura T., Kozone I., Takagi M., Shin-Ya K., Seto H., Hayakawa Y. Ammocidins B, C and D, new cytotoxic 20-membered macrolides from Saccharothrix sp. AJ9571 Ammocidins B, C and D from Saccharothrix sp. AJ9571. J. Antibiot. (Tokyo) 2009, 62:123-127.
110. Nam S.J., Gaudencio S.P., Kauffman C.A., Jensen P.R., Kondratyuk T.P., Marler L.E., Pezzuto J.M., Fenical W. Fijiolides A and B, inhibitors of TNF-α-induced NFκB activation, from a marine-derived sediment bacterium of the genus Nocardiopsis. J. Nat. Prod. 2010, 73(6):1080-1086.
111. Nasveschuk C.G., Ungermannova D., Liu X., Phillips A.J. A concise total synthesis of largazole, solution structure, and some preliminary structure activity relationships. Org. Lett. 2008, 10(16):3595-3598.
112. Newman D.J., Cragg G.M. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr. Med. Chem. 2004, 11:1693-1713.
113. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70(3):461-477.
114. Newman D.J., Hill R.T. New drugs from marine microbes: The tide is turning. J. Ind. Microbiol. Biotechnol. 2006, 33:539-544.
115. Ni X., Youe L., Chi Z., Li J., Wang X., Madzak C. Alkaline protease gene cloning from the marine yeast Aureobasidium pullulans HN2-3 and the protease surface display on Yarrowia lipolytica for bioactive peptide production. Mar. Biotechnol. 2009, 11:81-89.
116. Nogle L.M., Gerwick W.H. Somocystinamide A, a novel cytotoxic disulfide dimer from a Fijian marine cyanobacterial mixed assemblage. Org. Lett. 2002, 4(7):1095-1098.
117. Nussbaum F., Brands M., Hinzen B., Weigand S., Häbich D. Antibacterial natural products in medicinal chemistry-exodus or revival?. Angew. Chem. Int. Ed. Engl. 2006, 45(31):5072-5129.
118. Oh H., Jensen P.R., Murphy B.T., Fiorilla C., Sullivan J.F., Ramsey T., Fenical W. Cryptosphaerolide, a cytotoxic Mcl-1 inhibitor from a marine-derived ascomycete related to the genus Cryptosphaeria. J. Nat. Prod. 2010, 73(5):998-1001.
119. Okazaki T., Kitahara T., Okami Y. Studies on marine microorganisms. IV. A new antibiotic SS-228 Y produced by Chainia isolated from shallow sea mud. J. Antibiot. (Tokyo) 1975, 28(3):176-184.
120. Olano C., Lombó F., Méndez C., Salas J.A. Improving production of bioactive secondary metabolites in actinomycetes by metabolic engineering. Metab. Eng. 2008, 10(5):281-292.
121. Olano C., Méndez C., Salas J.A. Antitumor compounds from marine actinomycetes. Mar. Drugs 2009, 7(2):210-248.
122. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., Schacht A.L. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Dis. 2010, 9(3):203-214.
123. Peng X., Wang Y., Sun K., Liu P., Yin X., Zhu W. Cerebrosides and 2-pyridone alkaloids from the halotolerant fungus Penicillium chrysogenum grown in a hyperslaine medium. J. Nat. Prod. 2011, 74(5):1298-1302.
124. Perovic S., Wichels A., Schutt C., Gunnar G., Pahler S., Steffen R., Muller W.E.G. Neuroactive compounds produced by bacteria from the marine sponge Halichondria panacea: Activation of the neuronal MDA receptor. Environ. Toxicol. Pharmacol. 1998, 6:125-133.
125. Piel J., Hui D., Wen G., Butzke D., Platzer M., Fusetani N., Matsunaga S. Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei. Proc. Natl. Acad. Sci. USA 2004, 101(46):16222-16227.
126. Plavsic M., Terzic S., Ahel M., Van den Berg C.M.G. Folic acid in coastal waters of the Adriatic Sea. Mar. Freshw. Res. 2004, 53:1245-1252.
127. Porsby C.H., Webber M.A., Nielsen K.F., Piddock L.J., Gram L. Resistance and tolerance to tropodithietic acid, an antimicrobial in aquaculture, is hard to select. Antimicrob. Agents Chemother. 2011, 55(4):1332-1337.
128. Proksch P.R., Edrada A., Ebel R. Drugs from the seas-Current status and microbiological implications. Appl. Microbiol. Biotechnol. 2002, 59:25-34.
129. Prudhomme J., McDaniel E., Ponts N., Bertani S., Fenical W., Jensen P., Le Roch K. Marine actinomycetes: A new source of compounds against the human malaria parasite. PLoS One 2008, 3(6):e2335.
130. Radhakrishan M., Balagurunathan R., Selvakumar N., Doble M., Kumar V. Bioprospecting of marine derived actinomycetes with special reference to antimicrobial activity. Indian J. Geo-Mar. Sci. 2011, 40(3):407-410.
131. Rahman H., Austin B., Mitchel W., Morris P.C., Jamieson D.J., Adams D.R., Spragg A.M., Schweizer M. Novel anti-infective compounds from marine bacteria. Mar. Drugs 2010, 8:498-518.
132. Ramaswamy A.V., Flatt P.M., Edwards D.J., Simmons T.L., Han B., Gerwick W.H. The secondary metabolites and biosynthetic gene clusters of marine cyanobacteria. Applications in biotechnology. Frontiers in Marine Biotechnology 2006, 175-224. Horizon Biosciences, Norfolk, England. P. Proksch, W.E.G. Muller (Eds.).
133. Rester U. From virtuality to reality-Virtual screening in lead discovery and lead optimization: A medicinal chemistry perspective. Curr. Opin. Drug Discov. Devel. 2008, 11(4):559-568.
134. Rollinger J.M., Stuppner H., Langer T. Virtual screening for the discovery of bioactive natural products. Prog. Drug Res. 2008, 65(211):213-249.
135. Romanenko L.A., Uchino M., Kalinovskaya N.I., Mikhailov V.V. Isolation, phylogenetic analysis and screening of marine mollusc-associated bacteria for antimicrobial, hemolytic and surface activities. Microbiol. Res. 2008, 163(6):633-644.
136. Ruiz B., Chávez A., Forero A., García-Huante Y., Romero A., Sánchez M., Rocha D., Sánchez B., Rodríguez-Sanoja R., Sánchez S., Langley E. Production of microbial secondary metabolites: Regulation by the carbon source. Crit. Rev. Microbiol. 2010, 36(2):146-167.
137. Salvador L.A., Paul V.J., Luesch H. Caylobolide B, a macrolactone from symplostatin 1-producing marine cyanobacteria Phormidium spp. from Florida. J. Nat. Prod. 2010, 73(9):1606-1609.
138. Salvador L.A., Biggs J.S., Paul V.J., Luesch H. Veraguamides A-G, cyclic hexadepsipeptides from a dolastatin 16-producing cyanobacterium Symploca cf. hydnoides from Guam. J. Nat. Prod. 2011, 74(5):917-927.
139. Sandy M., Han A., Blunt J., Munro M., Haygood M., Butler A. Vanchrobactin and anguibactin siderophores produced by Vibrio sp. DS40M4. J. Nat. Prod. 2010, 73(6):1038-1043.
140. Schwartsmann G., Da Roccha A.B., Berlink R.G., Jimeno R.G. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2001, 2:221-225.
141. Singh S., Kate B.N., Banerjee U.C. Bioactive compounds from cyanobacteria and micro algae: An overview. Crit. Rev. Biotechnol. 2005, 25(3):73-95.
142. Socha A.M., Laplante K.L., Russell D.J., Rowley D.C. Structure-activity studies of echinomycin antibiotics against drug-resistant and biofilm-forming Staphylococcus aureus and Enterococcus faecalis. Bioorg. Med. Chem. Lett. 2009, 19(5):1504-1507.
143. Sudek S., Lopanik N.B., Waggoner L.E., Hildebrand M., Anderson C., Liu H., Patel A., Sherman D.H., Haygood M.G. Identification of the putative bryostatin polyketide synthase gene cluster from "Candidatus Endobugula sertula", the uncultivated microbial symbiont of the marine bryozoan Bugula neritina. J. Nat. Prod. 2007, 70(1):67-74.
144. Tan L.T. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry 2007, 68(7):954-979.
145. Tang R., Cohen S., Legrand O., Marie J.P. Antibody-drug conjugates in targeted therapy for cancer. Front. Drug. Des. Discov. 2007, 3(1):525-537.
146. Thornburg C.C., Zabriskie T.M., McPhail K.L. Deep-sea hydrothermal vents: Potential hot spots for natural products discovery?. J. Nat. Prod. 2010, 73(3):489-499.
147. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006, 8:343-375.
148. Trischman J.A., Tapiolas D.M., Jensen P.R., Dwight R., Fenical W., McKee T.C., Ireland C.M., Stout T.J., Clardy J. Salinamides A and B: Anti-inflammatory depsipeptides from a marine streptomycete. J. Am. Chem. Soc. 1994, 116(2):757-758.
149. Udwary D.W., Zeigler L., Asolkar R.N., Singan V., Lapidus A., Fenical W., Jensen P.R., Moore B.S. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. Proc. Natl. Acad. Sci. USA 2007, 104(25):10376-10381.
150. Uzair B., Ahmed N., Mohammad F.V., Ahmad V.U., Edwards D. Screening of marine bacteria of Pakistan coast for drug discovery potential. Proc. Pak. Acad. Sci. 2009, 46(3):137-144.
151. Veluri R., Oka I., Wagner-Döbler I., Laatsch H. New indole alkaloids from the North Sea bacterium Vibrio parahaemolyticus Bio249. J. Nat. Prod. 2003, 66(11):1520-1523.
152. Ventura M., Canchaya C., Tauch A., Chandra G., Fitzgerald G.F., Chater K.F., Van Sinderen D. Genomics of Actinobacteria: Tracing the evolutionary history of an ancient phylum. Microbiol. Mol. Biol. Rev. 2007, 71:495-548.
153. Williams P.G. Panning for chemical gold: Marine bacteria as a source of new therapeutics. Trends Biotechnol 2009, 27(1):45-52.
154. Wrasidlo W., Mielgo A., Torres V.A., Barbero S., Stoletov K., Suyama T.L., Klemke R.L., Gerwick W.H., Carson D.A., Stupack D.G. The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc. Natl. Acad. Sci. USA 2008, 105:2313-2318.
155. Ying Y., Taori K., Kim H., Hong J., Luesch H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J. Am. Chem. Soc. 2008, 130(26):8455-8459.
156. Zhang X., Wu F.X., Sun M., Wang Q.Y., Wang Y.J., Yang X. Study on antimicrobial and antiviral activities of lysozyme from marine strain S-12-86 in vitro. Agric. Sci. China 2008, 7(1):112-116.
157. Zheng J., Zhu H., Hong K., Wang Y., Liu P., Wang X., Peng X., Zhu W. Novel cyclic hexapeptides from marine-derived fungus, Aspergillus sclerotiorum PT06-1. Org. Lett. 2009, 11(22):5262-5265.
158. Zheng J., Xu Z., Wang Y., Hong K., Liu P., Zhu W. Cyclic tripeptides from the halotolerant fungus Aspergillus sclerotiorum PT06-1. J. Nat. Prod. 2010, 73(6):1133-1137.